Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
January 26, 2026 17:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
First in class study of an investigational ACTH receptor antagonist aims to…
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025 16:41 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show…
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025 16:28 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
